Silence Therapeutics Files 8-K/A Amendment on Officer/Director Changes
Ticker: SLNCF · Form: 8-K/A · Filed: Dec 22, 2025 · CIK: 1479615
| Field | Detail |
|---|---|
| Company | Silence Therapeutics PLC (SLNCF) |
| Form Type | 8-K/A |
| Filed Date | Dec 22, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, filing-amendment, officer-appointment, director-election
TL;DR
Silence Therapeutics amended its 8-K filing regarding leadership changes and compensation.
AI Summary
Silence Therapeutics plc filed an amendment (8-K/A) on December 22, 2025, to a report originally dated December 14, 2025. The amendment pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers.
Why It Matters
This filing indicates potential shifts in the company's leadership and executive compensation structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Amendments to 8-K filings concerning director and officer changes can signal internal restructuring or strategic shifts that may carry inherent risks.
Key Players & Entities
- Silence Therapeutics plc (company) — Registrant
- December 14, 2025 (date) — Earliest event reported
- December 22, 2025 (date) — Date of report (amendment filing)
FAQ
What specific items are being amended in the 8-K filing?
The amendment (8-K/A) pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers.
What is the original report date that this amendment refers to?
The earliest event reported in the original filing was December 14, 2025.
When was the amendment filed with the SEC?
The amendment was filed as of date December 22, 2025.
What is the primary business of Silence Therapeutics plc?
Silence Therapeutics plc is in the Pharmaceutical Preparations industry (SIC code 2834).
Where is Silence Therapeutics plc's principal executive office located?
The principal executive offices are located at 12 Hammersmith Grove, London, United Kingdom, W6 7AP.
Filing Stats: 857 words · 3 min read · ~3 pages · Grade level 12.8 · Accepted 2025-12-22 16:01:27
Filing Documents
- sln-20251214.htm (8-K/A) — 57KB
- 0001193125-25-328684.txt ( ) — 209KB
- sln-20251214.xsd (EX-101.SCH) — 55KB
- sln-20251214_htm.xml (XML) — 7KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Silence Therapeutics plc Date: December 22, 2025 By: /s/ Rhonda Hellums Name: Rhonda Hellums Title: Chief Financial Officer